Mycoplasma genitalium, an agent of reemerging sexually transmitted infections. Issue 10 (1st August 2017)

• Record Type: Journal Article
• Authors: Edouard, Sophie; Tissot‐Dupont, Hervé; Dubourg, Grégory; Bernard, Annick; Fournier, Pierre‐Edouard; Ravaux, Isabelle; Stein, Andreas; Raoult, Didier
• Is Part Of: Apmis. Volume 125:Issue 10(2017:Oct.)
• Page Start: 916
• Page End: 920
• Publication Date: 2017-08-01
• Subjects: Mycoplasma genitalium -- qPCR -- sexually transmitted infection; Pathology -- Periodicals; Microbiology -- Periodicals; Immunology -- Periodicals; 572
• DOI: 10.1111/apm.12731
• Languages: English
• ISSNs: 0903-4641

Abstract

Abstract : M. genitalium is a reemerging microorganism, responsible for sexually transmissible infections (STIs), with prevalence which varies depending on the country and population group studied. We report here M. genitalium prevalence among the specimens received for STI diagnosis in our routine microbiological laboratory in the university hospital in Marseille, France. We tested 4 624 samples from 3 793 patients using qPCR for M. genitalium, C . trachomatis, N. gonorrheae, T. pallidum . Of these samples, 528 (13.6%) patients were tested positive for at least one pathogen and 126 (3.3%) were positive for M. genitalium. M. genitalium is the second most prevalent micro‐organism detected in women after C. trachomatis (10.4%) and the third most prevalent in men after C. trachomatis (5.1%) and N. gonorrhoeae (4.4%). We observed no significant differences between the prevalence of M. genitalium in vaginal, urethral and urine specimens (p = 0.9). Prevalence of M. genitalium is significantly higher in patients aged between 10–30 years (4.1%) compared to those aged between 30 and 50 years (2.7%) (p = 0.02, RR = 1.54 [1.06–2.24]) and patients over 50 years of age (1.1%) (p = 0.003, RR= 3.98 [1.47–10.8]). M. genitalium is a common agent of STI, therefore we suggest that this micro‐organism should be systematically tested during chronic, recurrent, or antibiotic resistant genital infections and in populations at high‐risk of STIs.